Abstract 45P
Background
CD73 contributes to immune evasion in solid tumors by producing immune-suppressive adenosine in the tumor microenvironment. Herein, we describe CBO-212, a first-in-class CD73 targeting DFC, comprising a multi-valent conjugate of a novel small molecule CD73 inhibitor to a proprietary immune-silent hIgG1 Fc. CBO-212 combines the strengths of small molecule inhibitors and monoclonal antibodies targeting CD73 currently in clinical development with potential best-in-class activity.
Methods
Inhibition of CD73 was evaluated in cell-free and cell-based assays. Functional activity was measured in a PBMC rescue assay in the presence of AMP and binding to cancer cells was measured in the presence and absence of AMP by flow cytometry. CD73 internalization was determined using MDA-MB-231 cells. Pharmacokinetic (PK) studies were conducted in Balb/c mice. Plasma concentrations were measured using an anti-hIgG in combination with CD73 capture ELISA. Efficacy of CBO-212 was evaluated in syngeneic mouse models with established CT26.WT tumors.
Results
CBO-212 is a potent, AMP-competitive CD73 inhibitor. In cell-free and cell-based CD73 inhibition assays, CBO-212 IC50s were single digit nM, making them comparable or superior to small molecule inhibitors and anti-CD73 mAbs in clinical development. Unlike most anti-CD73 mAbs, CBO-212 demonstrated complete enzyme inhibition. Furthermore, CBO-212 demonstrated an EC50 in a human PBMC rescue assay of 6 nM, which was equivalent to small molecule inhibitor controls and approximately 100-fold more potent than anti-CD73 mAb controls. Additionally, CBO-212 triggered CD73 internalization, similar to some anti-CD73 mAbs. CBO-212 demonstrates long half-life and stability in mice. In a syngeneic mouse colon cancer model, a single 20 mg/kg dose of CBO-212 resulted in 37.9% tumor growth inhibition (TGI) relative to vehicle (P=0.0152).
Conclusions
CBO-212 demonstrated high potency in CD73 enzyme inhibition and functional PBMC rescue assays. The in vitro potency and favorable PK of CBO-212 translated to significant TGI in a syngeneic model with a single dose. Based on these results CBO-212 is being advanced as a clinical development candidate for the treatment of solid cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cidara Therapeutics.
Funding
Cidara Therapeutics.
Disclosure
J. Levin, S. Döhrmann, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, R. Grewal, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt: Financial Interests, Personal, Full or part-time Employment, Shareholder: Cidara Therapeutics.
Resources from the same session
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Deciphering the role of E2F transcription factor-1 in glutamine metabolism
Presenter: Katharina Huber
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract